Skip to content

Study · Not a test of the peptide alone · 1999

1 result

Characterization of Agouti-related protein binding to melanocortin receptors.

Yang YK, Thompson DA, Dickinson CJ, Wilken J, Barsh GS, Kent SB, Gantz I

Molecular endocrinology (Baltimore, Md.)1 Jan 1999Cited by 146 (Europe PMC)

PMID9892020 (opens in a new tab)DOI10.1210/mend.13.1.0223 (opens in a new tab)PepBankPUB-09892020
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Mechanism

    In binding assays, NDP-MSH displaced [125I]AGRP(87-132) from melanocortin receptors and AGRP(87-132) displaced [125I]NDP-MSH, indicating competitive binding.

    In plain wordsIn lab tests, NDP-MSH and the AGRP fragment competed for the same melanocortin receptor sites.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableCompetitive binding of NDP-MSH and AGRP(87-132) to melanocortin receptors
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Because [Nle4, D-Phe7] (NDP)-MSH displaces the binding of [125I]AGRP(87-132) to MCRs and AGRP(87-132) displaces the binding of [125I]NDP-MSH, we conclude that these molecules bind in a competitive fashion to melanocortin receptors.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.